Loading
Life sciences · Journal article
Otolaryngology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Objective This study aimed to investigate the potential benefit of survival of receiving timely postoperative radiation therapy (PORT) for head and neck cancer. Study Design Retrospective cohort. Setting National Cancer Database from 2004 to 2020. Methods Patients with a diagnosis of human papilloma virus (HPV)‐negative head and neck squamous cell carcinoma who received adjuvant radiation were included. Exposure groups included timely PORT or delayed PORT (≤42 or >42 days from surgery to radiotherapy, respectively). The primary outcome was 5‐year overall survival (OS). Inverse probability weighted models were used to estimate OS in the counter‐factual scenario that all patients started radiation within 6 weeks while adjusting for confounding. Observed OS was for the entire cohort, while predicted OS was for the generated model of universal timely PORT within 6 weeks. Survival analyses were replicated for demographic and clinical subgroups. Results In total, 58,184 patients were included. Patients were mostly male, white, and non‐Hispanic. The observed average 5‐year OS was similar to the predicted OS (observed 0.58, 95% CI: 0.57‐0.578; predicted 0.58, 95% CI: 0.57‐0.59). The largest predicted benefit for timely PORT was seen in privately insured, white, rural, males, and with hypopharyngeal and stage IV cancer, though confidence intervals included the null hypothesis. Conversely, black patients were predicted to have a decline in OS with timely PORT (observed 0.54, 95% CI 0.53‐0.56; predicted 0.50, 95% CI 0.46‐0.52). Conclusion For the overall cohort and other subgroups, even if optimally implemented, timely PORT is not predicted to improve OS. Modeling outcomes can guide resource allocation to the most impactful interventions.